Just some comments about the current conversation:
J.D. Your observation about the large markets for Ligand's pipeline is what has drawn a lot of us investors into the Ligand camp.
Also, while other sectors have been soaring to extremely, and unjustified, high evaluations, biotechs have been dumped upon. Ligand is not alone. If an investor concentrates on LGND only, without looking at the rest of the sector, they could make up almost any story to justify the low, IMO, LGND stock price. Compare LGND's valuation, and potential profitability, against some of these high-flying internet stocks. If Ligand would change it's name to L"Internet"gand, the stock price would be at $100! <g>
I've been waiting for the catalyst that will turn the biotech sector around. I was hoping for a few more blockbuster drug discoveries. But, this increase in generic drug prices, which could portend increases in the rest of the non-generic drug prices, might be the event to, hopefully, start this year's biotech rally.
Regards, Bob |
